Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen.

In the present legislations, the use of methods alternative to animal testing is explicitly encouraged, to use animal testing only 'as a last resort' or to ban it. The use of alternative methods to replace kinetics or repeated dose in vivo tests is a challenging issue. We propose here a strategy based on in vitro tests and QSAR (Quantitative Structure Activity Relationship) models to calibrate a dose-response model predicting hepatotoxicity. The dose response consists in calibrating and coupling a PBPK (physiologically-based pharmacokinetic) model with a toxicodynamic model for cell viability. We applied our strategy to acetaminophen and compared three different ways to calibrate the PBPK model: only with in vitro and in silico methods, using rat data or using all available data including data on humans. Some estimates of kinetic parameters differed substantially among the three calibration processes, but, at the end, the three models were quite comparable in terms of liver toxicity predictions and close to the usual range of human overdose. For the model based on alternative methods, the good adequation with the two other models resulted from an overestimated renal elimination rate which compensated for the underestimation of the metabolism rate. Our study points out that toxicokinetics/toxicodynamics approaches, based on alternative methods and modelling only, can predict in vivo liver toxicity with accuracy comparable to in vivo methods.

[1]  Hartmut Jaeschke,et al.  HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity , 2011, Hepatology.

[2]  C. Klaassen,et al.  Homeostasis of sulfate and 3'-phosphoadenosine 5'-phosphosulfate in rats after acetaminophen administration. , 1992, The Journal of pharmacology and experimental therapeutics.

[3]  B J Blaauboer,et al.  An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing. , 2005, Regulatory toxicology and pharmacology : RTP.

[4]  R. Calvo,et al.  Paracetamol metabolism in two ethnically different Spanish populations , 1996, European Journal of Drug Metabolism and Pharmacokinetics.

[5]  Ursula Gundert-Remy,et al.  Bisphenol A levels in blood depend on age and exposure. , 2009, Toxicology letters.

[6]  L. Gribaldo,et al.  Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[7]  S. Haddad,et al.  Physiologically-based pharmacokinetic modeling of pyrene in the rat. , 1998, Environmental toxicology and pharmacology.

[8]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[9]  R. Woutersen,et al.  Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation , 2012, Expert opinion on drug metabolism & toxicology.

[10]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[11]  C. Klaassen,et al.  Different mechanism of saturation of acetaminophen sulfate conjugation in mice and rats. , 1996, Toxicology and applied pharmacology.

[12]  G Levy,et al.  Dose- and time-dependent elimination of acetaminophen in rats: pharmacokinetic implications of cosubstrate depletion. , 1981, The Journal of pharmacology and experimental therapeutics.

[13]  L. Critchley,et al.  Differences in the single‐oral‐dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects , 2005, Journal of clinical pharmacy and therapeutics.

[14]  Malcolm Rowland,et al.  Rodgers T, Rowland M. 2006. Physiologically‐based Pharmacokinetic Modeling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–1257. , 2007 .

[15]  O. Fardel,et al.  Predicting in vivo gene expression in macrophages after exposure to benzo(a)pyrene based on in vitro assays and toxicokinetic/toxicodynamic models. , 2011, Toxicology letters.

[16]  Albrecht Poth,et al.  Implementation challenges for designing integrated in vitro testing strategies (ITS) aiming at reducing and replacing animal experimentation. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[17]  R. Blantz Acetaminophen: acute and chronic effects on renal function. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  M. Rawlins,et al.  Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration , 1977, European Journal of Clinical Pharmacology.

[19]  J. Bailar,et al.  Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[20]  Walter Schmitt,et al.  Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children , 2006, Clinical pharmacokinetics.

[21]  S. Fey,et al.  Determination of Drug Toxicity Using 3D Spheroids Constructed From an Immortal Human Hepatocyte Cell Line , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  C. Decker,et al.  Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. , 2001, Current opinion in chemical biology.

[23]  P. Sadler,et al.  Urinary excretion of acetaminophen and its metabolites as studied by proton NMR spectroscopy. , 1984, Clinical chemistry.

[24]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[25]  N. Kaneniwa,et al.  Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats , 1983, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  Bas J Blaauboer,et al.  Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice. , 2011, Regulatory toxicology and pharmacology : RTP.

[27]  Harvey J Clewell,et al.  Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results , 2012, Critical reviews in toxicology.

[28]  C. Klaassen,et al.  Glucuronidation and biliary excretion of acetaminophen in rats. , 1984, The Journal of pharmacology and experimental therapeutics.

[29]  M. Coughtrie,et al.  Assessment of cryopreserved human hepatocytes as a model system to investigate sulfation and glucuronidation and to evaluate inhibitors of drug conjugation , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  Valérie Zuang,et al.  Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.

[31]  Remigijus Didziapetris,et al.  Ionization-specific prediction of blood-brain permeability. , 2009, Journal of pharmaceutical sciences.

[32]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[33]  Phil Jeffrey,et al.  Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[34]  Yuichi Sugiyama,et al.  Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[35]  Don R. Maszle,et al.  MCSim: A Monte Carlo Simulation Program , 1997 .

[36]  Douglas Ferguson,et al.  Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  Paulo Paixão,et al.  Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. , 2012, International journal of pharmaceutics.

[38]  R. Brown,et al.  The effect of wheat bran and pectin on paracetamol absorption in the rat , 1979, British Journal of Nutrition.

[39]  Robert J Kavlock,et al.  Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[40]  Whelan Maurice,et al.  Hepatotoxicity Screening Taking a Mode-Of-Action Approach Using HepaRG Cells and HCA , 2012 .

[41]  Division on Earth Toxicity Testing in the 21st Century: A Vision and a Strategy , 2007 .

[42]  Sebastiaan A.L.M. Kooijman,et al.  The Analysis of Aquatic Toxicity Data , 1996 .

[43]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[44]  H. Esumi,et al.  Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of drugs. I: Studies by in vivo constant infusion , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[45]  Hartmut Jaeschke,et al.  Current issues with acetaminophen hepatotoxicity--a clinically relevant model to test the efficacy of natural products. , 2011, Life sciences.

[46]  Jan G. Hengstler,et al.  A physiologically based toxicokinetic modelling approach to predict relevant concentrations for in vitro testing , 2011, Archives of Toxicology.

[47]  Jerry L. Campbell,et al.  Quantitative interpretation of human biomonitoring data. , 2008, Toxicology and applied pharmacology.

[48]  D. Bailey,et al.  The Binding of Selected Therapeutic Drugs to Human Serum &agr;-1 Acid Glycoprotein and to Human Serum Albumin In Vitro , 2004, Therapeutic drug monitoring.